UNIVERSITY OF UTAH

The U.S. Supreme Court will hear a dispute over the FDA's refusal to allow two e-cigarette companies to sell flavored vape products, citing health risks to youths. The FDA appealed a lower court's ruling that it did not follow proper legal procedures when denying applications by Triton Distribution and Vapetasia. The case could further limit federal regulatory agencies' authority, with implications for the FDA's scientific decisions and enforcement of flavored e-cigarette regulations.

Eflornithine + lomustine combo shows clinically meaningful OS & PFS improvements in grade 3 IDH mutant astrocytoma patients, per Orbus Therapeutics' Phase 3 STELLAR study.

Eflornithine + lomustine combo showed clinically meaningful OS & PFS improvements in grade 3 IDH mutant astrocytoma patients, per Orbus Therapeutics' Phase 3 STELLAR study.

Howelsen Hill’s 109th winter season features 59 events, refurbishment of the Poma lift, and pumphouse improvements. Snowmaking is ongoing, and the Nordic Ambassador Program returns. Grooming remains at current levels despite requests for more frequent full grooms.

A phase II clinical trial explored a non-surgical chelation-based treatment for early cataracts, showing significant improvements in contrast sensitivity and lens clarity with minimal adverse effects. Future research is needed to determine long-term efficacy and broader applicability, with potential implications for delaying or reducing the need for cataract surgery.

The Department of Family and Preventive Medicine's three applications were accepted into the Vice President's Clinical and Translational Research Scholars Program, set to begin in 2025. Dr. Teresa DeAtley will focus on tobacco cessation treatments for TB in South Africa, Dr. Tiffany Ho on gender-affirming care safety and efficacy, and Dr. Jennifer Mundt on behavioral sleep medicine interventions, aiming for NIH funding.

Article reviews best hair loss serums for 2024, highlighting Hims, Hers, and Nutrafol. Discusses science-backed ingredients like minoxidil and caffeine, and factors such as foam vs. liquid, minimal irritants, and clinical trials. Prices range from $13–$150, with serums available in various forms. Experts recommend serums with proven ingredients and ease of application for effective hair regrowth.

Kim Hanson, MD, MHS, University of Utah Professor, receives prestigious Society Citation Award from IDSA. She also delivered the Joseph E. Smadel Lecture at IDSA's annual meeting, highlighting her leadership in infectious disease medicine. Hanson's contributions to patient care, research, and education are widely recognized.

The SynGAP Research Fund awarded grants to Dr. Clement Chow to advance therapeutic development for SYNGAP1-Related Disorders (SRD). Using a fruit fly model, Chow's team identified N-acetyl-L-leucine (NALL) as a promising treatment candidate. The follow-up grant supports further validation of NALL's therapeutic potential, aiming to fast-track treatments for SRD through drug repurposing.

The TALAPRO-2 trial, led by Neeraj Agarwal, found that a combination of enzalutamide and talazoparib significantly improves overall survival in prostate cancer patients compared to standard care. This novel therapy, approved by the FDA in 2023, offers new hope for late-stage prostate cancer patients.